Asset Management
Build Your Comparison
Side-by-side financial analysisStock Comparison
FHI vs GROW vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
Asset Management
Banks - Diversified
FHI vs GROW vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||
|---|---|---|---|
| Industry | Asset Management | Asset Management | Banks - Diversified |
| Market Cap | $4.49B | $39M | $908.57B |
| Revenue (TTM) | $1.86B | $11M | $280.33B |
| Net Income (TTM) | $399M | $3M | $57.05B |
| Gross Margin | 51.5% | 64.9% | 60.0% |
| Operating Margin | 27.4% | -1.4% | 25.9% |
| Forward P/E | 11.6x | — | 14.6x |
| Total Debt | $457M | $83K | $942.38B |
| Cash & Equiv. | $584M | $25M | $343.34B |
FHI vs GROW vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Federated Hermes, I… (FHI) | 100 | 249.2 | +149.2% |
| U.S. Global Investo… (GROW) | 100 | 163.2 | +63.2% |
| JPMorgan Chase & Co. (JPM) | 100 | 345.8 | +245.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FHI vs GROW vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
FHI has the current edge in this matchup, primarily because of its strength in income & stability and growth exposure.
- Dividend streak 3 yrs, beta 0.70, yield 2.4%
- Rev growth 11.0%, EPS growth 58.8%
- Lower volatility, beta 0.70, Low D/E 36.2%, current ratio 41.26x
GROW is the clearest fit if your priority is dividends.
- 2.9% yield, vs JPM's 1.8%
JPM is the clearest fit if your priority is long-term compounding and valuation efficiency.
- 481.2% 10Y total return vs FHI's 144.4%
- PEG 0.83 vs FHI's 1.19
- NIM 2.2% vs FHI's 0.5%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 11.0% NII/revenue growth vs GROW's -23.1% | |
| Value | Better valuation composite | |
| Quality / Margins | Efficiency ratio 0.3% vs GROW's 0.8% (lower = leaner) | |
| Stability / Safety | Beta 0.70 vs JPM's 0.87, lower leverage | |
| Dividends | 2.9% yield, vs JPM's 1.8% | |
| Momentum (1Y) | +43.1% vs JPM's +20.9% | |
| Efficiency (ROA) | Efficiency ratio 0.3% vs GROW's 0.8% |
FHI vs GROW vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FHI vs GROW vs JPM — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
GROW leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 25880.1x GROW's $11M. GROW is the more profitable business, keeping 29.1% of every revenue dollar as net income compared to JPM's 20.4%.
| Metric | |||
|---|---|---|---|
| RevenueTrailing 12 months | $1.9B | $11M | $280.3B |
| EBITDAEarnings before interest/tax | $527M | -$111,000 | $81.4B |
| Net IncomeAfter-tax profit | $399M | $3M | $57.0B |
| Free Cash FlowCash after capex | $307M | $464,000 | $100.9B |
| Gross MarginGross profit ÷ Revenue | +51.5% | +64.9% | +60.0% |
| Operating MarginEBIT ÷ Revenue | +27.4% | -1.4% | +25.9% |
| Net MarginNet income ÷ Revenue | +21.4% | +29.1% | +20.4% |
| FCF MarginFCF ÷ Revenue | +16.5% | +4.3% | +36.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +1.6% | +8.8% | +16.0% |
Valuation Metrics
FHI leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 11.5x trailing earnings, FHI trades at a 29% valuation discount to JPM's 16.2x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.92x vs FHI's 1.19x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||
|---|---|---|---|
| Market CapShares × price | $4.5B | $39M | $908.6B |
| Enterprise ValueMkt cap + debt − cash | $4.4B | $15M | $1.51T |
| Trailing P/EPrice ÷ TTM EPS | 11.51x | -124.00x | 16.22x |
| Forward P/EPrice ÷ next-FY EPS est. | 11.56x | — | 14.60x |
| PEG RatioP/E ÷ EPS growth rate | 1.19x | — | 0.92x |
| EV / EBITDAEnterprise value multiple | 7.82x | — | 18.52x |
| Price / SalesMarket cap ÷ Revenue | 2.48x | 4.65x | 3.25x |
| Price / BookPrice ÷ Book value/share | 3.51x | 0.92x | 2.51x |
| Price / FCFMarket cap ÷ FCF | 15.23x | — | 9.01x |
Profitability & Efficiency
FHI leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
FHI delivers a 29.5% return on equity — every $100 of shareholder capital generates $30 in annual profit, vs $7 for GROW. GROW carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), FHI scores 8/9 vs GROW's 2/9, reflecting strong financial health.
| Metric | |||
|---|---|---|---|
| ROE (TTM)Return on equity | +29.5% | +7.0% | +15.9% |
| ROA (TTM)Return on assets | +18.2% | +6.5% | +1.3% |
| ROICReturn on invested capital | +24.1% | -4.7% | +4.5% |
| ROCEReturn on capital employed | +26.3% | -6.2% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 2 | 5 |
| Debt / EquityFinancial leverage | 0.36x | 0.00x | 2.60x |
| Net DebtTotal debt minus cash | -$127M | -$24M | $599.0B |
| Cash & Equiv.Liquid assets | $584M | $25M | $343.3B |
| Total DebtShort + long-term debt | $457M | $83,000 | $942.4B |
| Interest CoverageEBIT ÷ Interest expense | 44.07x | 776.00x | 0.74x |
Total Returns (Dividends Reinvested)
JPM leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $23,548 today (with dividends reinvested), compared to $5,846 for GROW. Over the past 12 months, FHI leads with a +43.1% total return vs JPM's +20.9%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.7% vs GROW's 7.0% — a key indicator of consistent wealth creation.
| Metric | |||
|---|---|---|---|
| YTD ReturnYear-to-date | +14.2% | +27.8% | +0.8% |
| 1-Year ReturnPast 12 months | +43.1% | +31.8% | +20.9% |
| 3-Year ReturnCumulative with dividends | +69.2% | +22.5% | +138.8% |
| 5-Year ReturnCumulative with dividends | +101.8% | -41.5% | +135.5% |
| 10-Year ReturnCumulative with dividends | +144.4% | +96.0% | +481.2% |
| CAGR (3Y)Annualised 3-year return | +19.2% | +7.0% | +33.7% |
Risk & Volatility
FHI leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
FHI is the less volatile stock with a 0.70 beta — it tends to amplify market swings less than JPM's 0.87 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FHI currently trades 98.7% from its 52-week high vs GROW's 84.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.70x | 0.73x | 0.87x |
| 52-Week HighHighest price in past year | $59.83 | $3.65 | $338.09 |
| 52-Week LowLowest price in past year | $41.71 | $2.23 | $269.72 |
| % of 52W HighCurrent price vs 52-week peak | +98.7% | +84.9% | +96.2% |
| RSI (14)Momentum oscillator 0–100 | 67.2 | 68.7 | 72.1 |
| Avg Volume (50D)Average daily shares traded | 734K | 28K | 7.4M |
Analyst Outlook
Evenly matched — GROW and JPM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: FHI as "Hold", JPM as "Buy". Consensus price targets imply 4.5% upside for JPM (target: $340) vs -2.7% for FHI (target: $58). For income investors, GROW offers the higher dividend yield at 2.92% vs JPM's 1.83%.
| Metric | |||
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | — | Buy |
| Price TargetConsensus 12-month target | $57.50 | — | $339.75 |
| # AnalystsCovering analysts | 21 | — | 61 |
| Dividend YieldAnnual dividend ÷ price | +2.4% | +2.9% | +1.8% |
| Dividend StreakConsecutive years of raises | 3 | 0 | 15 |
| Dividend / ShareAnnual DPS | $1.40 | $0.09 | $5.95 |
| Buyback YieldShare repurchases ÷ mkt cap | +5.9% | +5.0% | +3.8% |
FHI leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). GROW leads in 1 (Income & Cash Flow). 1 tied.
FHI vs GROW vs JPM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is FHI or GROW or JPM a better buy right now?
For growth investors, Federated Hermes, Inc.
(FHI) is the stronger pick with 11. 0% revenue growth year-over-year, versus -23. 1% for U. S. Global Investors, Inc. (GROW). Federated Hermes, Inc. (FHI) offers the better valuation at 11. 5x trailing P/E (11. 6x forward), making it the more compelling value choice. Analysts rate JPMorgan Chase & Co. (JPM) a "Buy" — based on 61 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — FHI or GROW or JPM?
On trailing P/E, Federated Hermes, Inc.
(FHI) is the cheapest at 11. 5x versus JPMorgan Chase & Co. at 16. 2x. On forward P/E, Federated Hermes, Inc. is actually cheaper at 11. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 83x versus Federated Hermes, Inc. 's 1. 19x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — FHI or GROW or JPM?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +135. 5%, compared to -41. 5% for U. S. Global Investors, Inc. (GROW). Over 10 years, the gap is even starker: JPM returned +481. 2% versus GROW's +96. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — FHI or GROW or JPM?
By beta (market sensitivity over 5 years), Federated Hermes, Inc.
(FHI) is the lower-risk stock at 0. 70β versus JPMorgan Chase & Co. 's 0. 87β — meaning JPM is approximately 25% more volatile than FHI relative to the S&P 500. On balance sheet safety, U. S. Global Investors, Inc. (GROW) carries a lower debt/equity ratio of 0% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — FHI or GROW or JPM?
By revenue growth (latest reported year), Federated Hermes, Inc.
(FHI) is pulling ahead at 11. 0% versus -23. 1% for U. S. Global Investors, Inc. (GROW). On earnings-per-share growth, the picture is similar: Federated Hermes, Inc. grew EPS 58. 8% year-over-year, compared to -126. 6% for U. S. Global Investors, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — FHI or GROW or JPM?
Federated Hermes, Inc.
(FHI) is the more profitable company, earning 22. 3% net margin versus -4. 0% for U. S. Global Investors, Inc. — meaning it keeps 22. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FHI leads at 29. 5% versus -35. 3% for GROW. At the gross margin level — before operating expenses — FHI leads at 73. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is FHI or GROW or JPM more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 83x versus Federated Hermes, Inc. 's 1. 19x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Federated Hermes, Inc. (FHI) trades at 11. 6x forward P/E versus 14. 6x for JPMorgan Chase & Co. — 3. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for JPM: 4. 5% to $339. 75.
08Which pays a better dividend — FHI or GROW or JPM?
All stocks in this comparison pay dividends.
U. S. Global Investors, Inc. (GROW) offers the highest yield at 2. 9%, versus 1. 8% for JPMorgan Chase & Co. (JPM).
09Is FHI or GROW or JPM better for a retirement portfolio?
For long-horizon retirement investors, JPMorgan Chase & Co.
(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87), 1. 8% yield, +481. 2% 10Y return). Both have compounded well over 10 years (JPM: +481. 2%, GROW: +96. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between FHI and GROW and JPM?
Both stocks operate in the Financial Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: FHI is a small-cap deep-value stock; GROW is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.